In its latest research note, the bank pointed to broadly stable mobile pricing across the main operators. Telecom Italia (BIT ...

Finland’s Kojamo (HE: KOJAMO) reported a modest rise in revenue but weaker profitability in the second quarter of 2025, as ...

Investing.com -- The European Union-United States trade deal does not currently include the wine and spirits sector, European Union Trade Commissioner Maros Sefcovic said on Thursday. Sefcovic noted ...

Novonesis narrowed its full-year organic sales growth outlook to 6–8% from 5–8% and maintained its EBITDA margin guidance of ...

Investing.com -- Barclays (LON: BARC) has raised its forecast for euro area inflation in 2025, now expecting headline consumer prices to average 2.1% compared with the 2% projection it published in ...

Investing.com -- Israel has given final approval to a project that will expand settlements in the West Bank, a move critics say undermines prospects for Palestinian statehood.

The joint statement noted that the U.S. agreed to apply only pre-existing Most Favored Nation (MFN) tariffs of below 15% from September 1 on EU aircraft and parts, generic pharmaceuticals and ...

Investing.com -- Sarepta Therapeutics (NASDAQ: SRPT) stock declined 3.3% in pre-market trading Thursday after the company announced a refinancing of approximately $700 million of its 1.25% Convertible ...

During the meeting, Jaishankar reaffirmed India’s ambition to expand bilateral trade with Russia, with a particular focus on increasing Indian exports to correct the current trade imbalance.

From a sectoral perspective, Consumer Discretionary faces “a combination of margin pressure and weaker pricing power,” leading to underperformance. Industrials are seen benefiting from near-shoring ...

Investing.com - The Marzetti Company (NASDAQ: MZTI) shares fell 3% on Thursday after the specialty food manufacturer reported fourth-quarter earnings that missed analyst expectations, despite posting ...

Investing.com -- Morgan Stanley (NYSE: MS) has initiated coverage of Trevi Therapeutics (NASDAQ: TRVI) with an “overweight” rating and a price target of $18. The brokerage flags Trevi’s development of ...